[ad_1]
German biotech company CureVac has announced that its experimental vaccine developed against the COVID-19 disease has the ability to remain stable at 5 degrees Celsius for at least three months, making it easier to transport than vaccines created by other rivals in the world. pharmaceutical industry, informs Reuters.
CureVac, which will soon begin Phase 3 clinical trials, announced that the stability of this liquid vaccine has been tested at the intended storage concentrations and that the drug has been stored at 5 degrees Celsius, but also at temperatures below -60. degrees Celsius, writes agerpres.ro.
Read also: Dan Barna thunder and lightning: “The old PSD, PNL and UDMR parties boycotted the No Penalties referendum”
The tests demonstrated the vaccine’s stability at room temperature for up to 24 hours, CureVac representatives said Thursday.
American group Pfizer and its German partner BioNTech became the first pharmaceutical companies in the world on Monday to publish a series of data showing that their experimental vaccine has been shown to be effective in large phase 3 clinical trials.
Read also: Alexandru Rafila: “The Ministry of Health needs a clearer strategy and better coordination”
However, their vaccine must be stored at minus 70 degrees Celsius. Prior to administration, the Pfizer vaccine can be stored in a regular refrigerator for up to five days or in thermal transport containers for up to 15 days.
CureVac used a technology based on messenger RNA therapies to produce its vaccine, the same approach used by Pfizer-BioNTech and Moderna.
Read also: “He carried out the president’s order” – Traian Băsescu, on Florian Coldea’s involvement in Iraq, where the former SRI chief operations officer had no competence.
.
[ad_2]
Source link
